Skip to main content

Table 1 Demographic features of different cohorts

From: Lipocalin 2 links inflammation and ankylosis in the clinical overlap of inflammatory bowel disease (IBD) and ankylosing spondylitis (AS)

  AS alone AS-IBD MBP IBD HC
N (male/female) 462 (350/112) 57 (44/13) 52 (26/26) 85 (85/0) 158 (106/52)
HLA-B27 positivity 78% (357/456) 56% (32/57) 0% (0/52) N/A 0% (0/158)
CRP (mg/L) 13.9 ± 21.1 15.4 ± 17.3 2.13 ± 2.8 N/A N/A
ESR (mm/hour) 13.5 ± 15.6 14.4 ± 17.2 6.2 ± 4.9 N/A N/A
BASDAI 4.8 ± 2.5 4.5 ± 2.6 4.8 ± 2 N/A N/A
Biologics* 43% (200/462) 74% (42/57) N/A N/A N/A
Disease duration (years) 2–62 2–53 N/A N/A N/A
  1. *Biologics include infliximab, adalimumab, golimumab, and etanercept